#	Pagina
attuale pagina	/open-h2020/projects/193253/index.html

Opendata, web and dolomites

SECURE SIGNED

Secondary prEvention of CardiovascUlaR disease in the Elderly trial

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Outcomes and
results

SECURE project word cloud

Explore the words cloud of the SECURE project. It provides you a very rough idea of what is the project "SECURE" about.

lipids events nonfatal disease primary drafting standard ageing significantly stakeholders secure myocardial guidance infarction globally subjects recommendations italy poland eligible regional outcomes efficacy strategies heart hospitalisation blood intervention treatment effectiveness strategy guidelines coronary reference tackling fixed suboptimal polypill involve secondary death reduces responsible separately population endpoints requiring ge adherence 65 elderly half revascularisation trial germany risk hungary cvd czech causes created therapy diseases older benefit pressure while seven intermediate compare adults patients pharmacoeconomic survival countries france worldwide deaths stroke first differences spain medications prevention dose despite serve components fdc republic chronic clinical effect framework combination cardiovascular worsening

Project "SECURE" data sheet

The following table provides information about the project.

Coordinator	CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 website: www.cnic.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.secure-h2020.eu/
Total cost	6˙898˙301 €
EC max contribution	5˙998˙786 € (87%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2014-two-stage
Funding Scheme	RIA
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 website: www.cnic.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	coordinator	1˙465˙972.00
2	CHARITE - UNIVERSITAETSMEDIZIN BERLIN CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 website: www.charite.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	1˙096˙546.00
3	ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI Organization address address: VIA MARIO NEGRI 2 city: MILANO postcode: 20156 website: www.marionegri.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	1˙034˙362.00
4	SERVICIO MADRILENO DE SALUD SERVICIO MADRILENO DE SALUD Organization address address: PLAZA CARLOS TRIAS BERTRAN 7 city: MADRID postcode: 28020 website: http://cort.as/10Yf contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (MADRID)	participant	794˙166.00
5	ARTTIC ARTTIC Organization address address: RUE DU DESSOUS DES BERGES 58A city: PARIS postcode: 75013 website: www.arttic.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	391˙512.00
6	FERRER INTERNATIONAL FERRER INTERNATIONAL Organization address address: AVENIDA DIAGONAL 549 city: BARCELONA postcode: 8029 website: www.ferrergrupo.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	263˙574.00
7	CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON Organization address address: PLACE SAINT JACQUES 2 city: BESANCON CEDEX postcode: 25030 website: www.chu-besancon.fr/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (BESANCON CEDEX)	participant	232˙609.00
8	VSEOBECNA FAKULTNI NEMOCNICE V PRAZE VSEOBECNA FAKULTNI NEMOCNICE V PRAZE Organization address address: U NEMOCNICE 2 city: PRAHA 2 postcode: 12808 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (PRAHA 2)	participant	219˙883.00
9	UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU Organization address address: UL PASTEURA 1 city: WROCLAW postcode: 50 367 website: www.am.wroc.pl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PL (WROCLAW)	participant	211˙251.00
10	SEMMELWEIS EGYETEM SEMMELWEIS EGYETEM Organization address address: ULLOI UTCA 26 city: BUDAPEST postcode: 1085 website: www.sote.hu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	HU (BUDAPEST)	participant	184˙650.00
11	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER Organization address address: KEPPEL STREET city: LONDON postcode: WC1E 7HT website: http://www.lshtm.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	104˙258.00

Map

Project objective

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.

Deliverables

List of deliverables.
SECURE poster	Websites, patent fillings, videos etc.	2020-04-01 17:10:11
Project leaflet	Websites, patent fillings, videos etc.	2020-04-01 17:10:11
Detailed dissemination plan	Documents, reports	2020-04-01 17:10:11
Public website	Websites, patent fillings, videos etc.	2020-04-01 17:10:11

Take a look to the deliverables list in detail: detailed list of SECURE deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Borja IbaÃ±ez, JosÃ© M Castellano, Valentin Fuster Polypill strategy at the heart of cardiovascular secondary prevention published pages: 9-10, ISSN: 1355-6037, DOI: 10.1136/heartjnl-2018-313464	Heart 105/1	2020-04-01
2019	Jose M. Castellano, Juan Verdejo, Salvador Ocampo, Marco Martinez Rios, Enrique GÃ³mez-Ãlvarez, Gabriela Borrayo, Emilio Ruiz, Borja IbÃ¡Ã±ez, Valentin Fuster, Misael Arroyo, Maria Teresa Colosia, Juan E. Becerril, Roberto VÃ¡zquez, Elias Rodriguez, Alejandro Rodriguez, Rafael MÃ¡rquez, Enrique Gomez, Juan M. GonzÃ¡lez, Jose L. Ubiarco, Jose F. Barrera, Bertha Vitela, Laura A. Aranda, VÃctor Pe Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study published pages: 31-40, ISSN: 0188-4409, DOI: 10.1016/j.arcmed.2019.04.001	Archives of Medical Research 50/1	2020-04-01
2017	Ruth Webster, Jose M Castellano, Oyere K Onuma Putting polypills into practice: challenges and lessons learned published pages: 1066-1074, ISSN: 0140-6736, DOI: 10.1016/s0140-6736(17)30558-5	The Lancet 389/10073	2020-04-01
2017	JosÃ© M Castellano, ValentÃn Fuster, Catriona Jennings, Eva Prescott, HÃ©ctor Bueno Role of the polypill for secondary prevention in ischaemic heart disease published pages: 44-51, ISSN: 2047-4873, DOI: 10.1177/2047487317707324	European Journal of Preventive Cardiology 24/3_suppl	2020-04-01
2017	Mrs. Fiona Ecarnot, Prof. FranÃ§ois Schiele La polypill Ã travers les rÃ©sultats de l\'Ã©tude HOPE 3 published pages: 12-16, ISSN: 0761-5035, DOI:	La Lettre du Cardiologue NÂ°505 / May 2017	2020-04-01
2015	JosÃ© M. Castellano, ValentÃn Fuster Polypill, el policomprimido cardiovascular: del concepto a la realidad en EspaÃ±a published pages: 19-24, ISSN: 1131-3587, DOI: 10.1016/S1131-3587(16)30005-X	Revista EspaÃ±ola de CardiologÃa Suplementos 15	2020-04-01
2015	Juan Tamargo, JosÃ© M. Castellano, ValentÃn Fuster The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention published pages: S15-S23, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31028-7	International Journal of Cardiology 201	2020-04-01
2015	JosÃ© M. Castellano, HÃ©ctor Bueno, ValentÃn Fuster The cardiovascular polypill: clinical data and ongoing studies published pages: S8-S14, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31027-5	International Journal of Cardiology 201	2020-04-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SECURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More